CTIS.eu › Cities › France › Bordeaux
Bordeaux
France
1,096 total trials
483 recruiting
Filter these 1,096 trials by phase, condition, sponsor and more.
Open in Search →
2024-517281-42-00
7
2025-11-12
Advanced solid tumors
2024-517411-73-00
6
2025-11-12
Patient with medium or high risk for pneumococcal invasive infection
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
2024-519345-30-00
5
2025-11-12
IgA nephropathy
2024-519871-24-00
10
2025-11-11
Breast cancer
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
2025-522169-31-00
4
2025-10-30
Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
2023-504829-39-00
5
2025-10-28
respiratory distress due to upper airway obstruction in child
2025-520694-39-00
4
2025-10-24
Metastatic or locally advanced irresectable (stage IV) gastric cancer
2023-503283-17-00
6
2025-10-22
Women who delivered by caesarean and have a moderate postpartum iron d
2024-520413-53-00
5
2025-10-21
Spinocerebellar ataxia
2023-509175-16-00
5
2025-10-14
Sickle cell disease
2023-509728-16-00
4
2025-10-10
advanced Parkinson’s disease
2025-521147-21-00
4
2025-10-08
Lung Cancer
2023-509275-17-00
5
2025-10-06
Relapsing multiple sclerosis
2024-517632-22-00
5
2025-10-06
Hidradenitis Suppurativa
2024-511871-13-00
6
2025-10-02
Postmenopausal osteoporosis
2024-519445-29-00
1
2025-10-02
Solid Tumors
2024-512177-27-01
5
2025-09-29
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invas
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
2025-520740-16-00
5
2025-09-19
Primary Aldosteronism defined by excess aldosterone secretion
Showing 265–288 of 1,096 trials